Key facts: GSK buyback boosts treasury shares; U.S. committee to vote on vaccine delay

TradingView
2025.12.03 01:03
portai
I'm PortAI, I can summarize articles.

On December 2, 2025, GSK plc acquired 11,346,733 shares in its buyback program, increasing treasury shares to 236,811,577, or 5.81% of total voting rights.1GSK produces the hepatitis B vaccine, recommended for American children in three doses. A U.S. committee will vote on delaying these shots, potentially affecting vaccine supply chains.2

  • On December 2, 2025, GSK plc acquired 11,346,733 shares in its buyback program, increasing treasury shares to 236,811,577, or 5.81% of total voting rights.1
  • GSK produces the hepatitis B vaccine, recommended for American children in three doses. A U.S. committee will vote on delaying these shots, potentially affecting vaccine supply chains.2
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer